Figure 7
Optimized LL-CFA/I therapy is protective at 30 wks. Four wk-old NOD females were orally dosed with 5 × 107 CFUs of LL-CFA/I, LL vector, or PBS. Additional doses were given every 2 wks. (A) Blood glucose levels of individual mice treated with LL-CFA/I, LL vector, or PBS (n = 10/group) are depicted. Values above the dotted lines are considered hyperglycemic. (B) Summary of disease incidence of mice given the various treatments. Dotted line represents incidence of mice treated with LL-CFA/I. At 30 wks or when hyperglycemic mice were euthanized, (C) splenic and (D) PaLN lymphocytes were stimulated with anti-CD3 and anti-CD28 mAbs to assess extent of IL-10, TGF-β, IL-17, IL-13, and IL-4 production. Pancreatic lymphocytes were purified and analyzed for expression of (E) Foxp3 and Tbet expression; PBS (n = 5), LL vector (n = 5), and LL-CFA/I (n = 7). *p < 0.05 for LL-CFA/I vs PBS; #p < 0.05 for LL-CFA/I vs LL vector.
